Major ALS drug trial tests potential to slow disease progression
NCT ID NCT00330681
Summary
This Phase 3 study tested whether the drug MCI-186 could help control ALS symptoms and slow disease progression. 206 people with ALS received either the drug or a placebo through daily IV drips for 24 weeks. Researchers measured changes in physical function, breathing ability, and quality of life to see if the treatment made a meaningful difference.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.